Chronic mucocutaneous candidiasis (CMC) is a condition characterised by recurrent or persistent infections of the skin, nails and mucous membranes caused predominantly by Candida species.

Chronic mucocutaneous candidiasis is a very rare genetic condition resulting in a T-lymphocyte-mediated immune disorder, the details of which are beyond the scope of this column.

Chronic mucocutaneous candidiasis (CMC) refers to a group of disorders that feature persistent, debilitating, and recurrent infections of the skin, nails, and mucous membranes.

An 11-year-old Hispanic boy was referred to our hospital for evaluation of mucocutaneous candidiasis, failure to thrive, type 1 diabetes, secretory diarrhea and hemolytic anemia. The patient had ...

Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis (CMC), which is characterized by chronic or recurrent infections of the skin, nails, and oral and genital mucosae ...

CMC denotes chronic mucocutaneous candidiasis, CNS central nervous system, Covid-19 coronavirus disease 2019, and MSMD mendelian susceptibility to mycobacterial diseases.

Ruxolitinib, an inhibitor of Janus kinase (JAK) 1 and 2, was previously shown to decrease many of the symptoms of this disorder, including chronic mucocutaneous candidiasis, autoimmune enteropathy ...

– Matinas BioPharma to commence 6-month safety open-label extension to Phase 2a study with National Institutes of Health (NIH) – – On track to report Phase 2a topline data for MAT2203 in 2Q ...

–100% (three out of three) of patients have now met the primary endpoint in achieving ≥ 50% clinical response with MAT2203 – – Study has met predetermined statistical endpoint for success ...